• Best stocks to buy now
  • Contact
  • Disclaimer
Saturday, May 27, 2023
No Result
View All Result
Best Stocks
  • News
  • Best stocks to buy now
  • Categories
    • Crypto
    • Dow Jones today
    • Pre-IPO and startups
    • Tech stocks
    • Utility stocks
  • Best Stocks toolsHOT
    • Stock News Sentiment
    • Stock Fundamentals Checker
    • Price Targets
    • Social Sentiments Checker
    • Indices
  • About us
    • About
    • Contact
Best Stocks
No Result
View All Result
Home News

Mirae Asset Global Investments Co. Ltd. Decreases Position in Invitae Corp.(NYSE:NVTA) – A Closer Look at the Company’s Financial Health

Yasmim Mendonça by Yasmim Mendonça
May 26, 2023
in News
Reading Time: 3 mins read
A A
0
ACI stock news
0
SHARES
28
VIEWS
Share on FacebookShare on Twitter

In the world of finance, there are always transactions taking place, investments being made and decisions being taken. One such decision was that of Mirae Asset Global Investments Co. Ltd., one of the leading institutional investors in the market, who decreased its position in shares of Invitae Co.(NYSE:NVTA) by 21.7% during the 4th quarter of last year.

According to its most recent filing with the Securities and Exchange Commission, Mirae Asset Global Investments Co. Ltd. owned about 0.58% of Invitae worth $2,633,000 as of its most recent filing with the Securities and Exchange Commission.

Invitae Corp. is a leading provider of genetic information into mainstream medical practice; they specialize in providing comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric and rare diseases.

The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

While this news may be cause for concern to some shareholders at first glance, it is important to note that Invitae’s stock has seen significant fluctuations over the past year with a low of $1.05 and a high of $9.00.

Shares opened at $1.08 on Friday with a 50-day moving average price of $1.32 and a 200-day moving average price of $1.94.

It is also worth mentioning that Invitae has maintained strong financials with a current ratio of 2.65 which indicates its ability to meet short-term obligations; it also has a quick ratio (which measures a company’s ability to meet short term obligations using only its most liquid assets)of 2..55,making them financially solvent amidst all market uncertainties.They have managed to maintain their debt-to-equity ratio at a high percentage which points out future growth and capital expansion plans.

In conclusion, while Mirae Asset Global Investments Co. Ltd.’s decision to decrease its position in Invitae may cause concern for some investors, it is important to look at the bigger picture and consider all factors. As a company that has positioned itself for growth and success in the medical research space, Invitae continues to remain an attractive investment opportunity with high potential gains on investments in their future. And with impressive financial ratios, they have proven that they can sustain themselves throughout market uncertainties.The figures certainly speak for themselves!

Institutional Investors Boost Holdings in Genetic Information Provider, Invitae Corp.



San Francisco-based Invitae Corp. is a leading provider of genetic information for mainstream medical purposes. The company has recently received a boost from institutional investors, with a handful of hedge funds boosting their holdings in the company by as much as 219.2% during the third quarter of 2020. In particular, MetLife Investment Management LLC boosted its position by 33.5% during the same period, while Victory Capital Management Inc.’s stake increased by over two-fold.

However, the company has experienced some insider selling as well. CAO Robert F. Werner sold more than 21,000 shares of Invitae stock on May 16th to garner $25,870 in proceeds while CFO Yafei Wen sold about twice the number of shares at an average price of $1.99, netting $86,469.

Invitae’s performance has been mediocre as evident from its negative return on equity and net margin of more than -600%. However, it beat earnings estimates for Q1 2020 with (-$0.37) per share compared to analysts’ projected losses of (-$0.41), on revenue amounting to $117.36 million.

Several analysts have expressed negative views about Invitae’s stock outlook with rating offers ranging from “sell” to “underperform.” Experts calculated that the consensus target price for Invitae Shares is $3.88 with an analyst consensus rating of “hold,” according to Bloomberg.com.

The company was established in January 2010 by its founders Randal W Scott and Sean George and currently provides comprehensive panels that help diagnose hereditary conditions including cancer, cardiology, neurology, pediatric diseases, and rare ailments.

Tags: NVTA
Yasmim Mendonça

Yasmim Mendonça

Yasmine's focus is on uncovering early-stage ideas with the potential to have a lasting impact. Her educational background includes a bachelor's degree in finance, an MBA, and two tests completed - the CFA and CMT.

Discussion about this post

DISCLAIMER

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

The Best Stocks, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

READ MORE

Categories

Best Stocks to buy now
Crypto
Dow Jones Today
Pre-IPO and Startups
Tech stocks
Utility Stocks

Data and Tools
Stock Forecast
Dow Jones Today

Follow us on Social Media
Facebook – YouTube – Twitter

Write for us
Finance – Business

Best Stocks to Buy Now

We are a financial media dedicated to providing stock recommendations, news, and real-time stock prices.

  • Disclaimer
  • Privacy Policy
  • Best stocks to buy now
  • Contact
  • Write for us – Finance, Crypto

© 2023 Best Stocks

No Result
View All Result
  • Home
  • News
  • Best stocks to buy now
  • Categories
    • Crypto
    • Dow Jones Today
    • Pre-IPO and Startups
    • Tech stocks
    • Utility Stocks
  • Best Stocks Tools
    • Stock News Sentiment
    • Stock Fundamentals Checker
    • Price Targets
    • Social Sentiments Checker
    • Indices
  • About us
    • About
    • Contact

© 2023 Best Stocks